The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients - Takeaways - MDSpire

The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients

  • By

  • Jesús Silva-Rodríguez

  • Miguel A Labrador-Espinosa

  • Linda Zhang

  • Sandra Castro-Labrador

  • Francisco Javier López-González

  • Alexis Moscoso

  • Pascual Sánchez-Juan

  • Michael Schöll

  • Michel J Grothe

  • for the Alzheimer’s Disease Neuroimaging Initiative

  • January 31, 2025

  • 0 min

Share

  • 1

    Lewy body pathology co-occurs in approximately 50% of Alzheimer's disease patients and influences clinical outcomes in amnestic impairments.

  • 2

    Patients with both Alzheimer's and Lewy body pathology exhibit worse global cognition and faster cognitive decline compared to those with Alzheimer's alone.

  • 3

    Distinct neuroimaging patterns reveal that Alzheimer's patients with Lewy body pathology show severe hypometabolism, while those with pure Lewy body pathology have a unique posterior-occipital pattern

  • 4

    Cognitive profiles differ significantly; Alzheimer's patients with Lewy bodies maintain memory deficits, while those with pure Lewy bodies display more dysexecutive and visuospatial impairments.

  • 5

    The presence of Lewy body pathology may alter the clinical phenotype in Alzheimer's, affecting diagnosis and prognosis in patients with amnestic syndromes.

Original Source(s)

The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients

  • by Jesús Silva-Rodríguez, Miguel A Labrador-Espinosa, Linda Zhang, Sandra Castro-Labrador, Francisco Javier López-González, Alexis Moscoso, Pascual Sánchez-Juan, Michael Schöll, Michel J Grothe, for the Alzheimer’s Disease Neuroimaging Initiative

  • January 31, 2025

Related Content

Acceptability of Technologies to Support Early Dementia Detection: Qualitative Study With the Boston University Alzheimer’s Disease Center Cohort

Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone?

Editorial: Transforming neurological recovery: the promise of regenerative neurorehabilitation